|
1）Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy – A Heart Failure Society of America Practice Guideline. J Card Fail. 2009; 15: 83-97
|
|
|
|
2）Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013; 381: 242-55
|
|
|
|
|
|
3）Krehl, L. Beitrag zur Kentniss der idiopathischen Helz-muskelerk-rankungen. Dtsch Arch Klin Med. 1891; 48: 414-31
|
|
|
|
|
|
4）Report of the WHO/ISFC task force on definition and classification of cardiomyopathies. Br Heart J. 1980; 44: 672-3
|
|
|
|
|
|
5）Richardson P, McKenna RW, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996; 93: 841-2
|
|
|
|
|
|
6）Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation. 2006; 113: 1807-16
|
|
|
|
|
|
7）Elliott P, Anderson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2008; 29: 270-6
|
|
|
|
|
|
8）Arbustini E, Narula N, Dec GW, et al. The MOGE (S) classification for a phenotype–genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol. 2013; 62: 2046-72
|
|
|
|
|
|
9）厚生労働省難治性疾患克服事業, 特発性心筋症調査研究班. 心筋症—診断の手引きとその解説. かりん舎. 2005
|
|
|
|
|
|
10）Anja AT, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain gene missense mutation. Cell. 1990; 62: 999-1006
|
|
|
|
|
|
11）Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy A personal history. Circ Res. 2011; 108: 743-50
|
|
|
|
|
|
12）Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet. 2012; 91: 513-9
|
|
|
|
|
|
13）Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol. 2004; 44: 2192-201
|
|
|
|
|
|
14）Golbus JR, Puckelwartz MJ, Fahrenbach JP, et al. Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet. 2012; 5: 391-9
|
|
|
|
|
|
15）Herman DS, Lam L, Taylor MRG, et al. Truncations of titin causing dilated cardiomyopathy. N Eng J Med. 2012; 366: 619-28
|
|
|
|
|
|
16）Norton N, Li D, Rampersaud E, et al. Exome sequencing and genome-wide linkage analysis in 17 families illustrates the complex contribution of TTN truncating variants to dilated cardiomyopathy: Circ Cardiovasc Genet. 2013; 6: 144-53
|
|
|
|
|
|
17）Xu T, Yang Z, Vatta M, et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2010; 55: 587-97
|
|
|
|
|
|
18）Kapplinger JD, Landstorm AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia–associated mutations from background genetic noise: J Am Coll Cardiol. 2011; 57: 2317-27
|
|
|
|
|
|
19）Tariq M, Belmont JW, Lalani S, et al. SHROOM3 is a novel candidate for heterotaxy identified by whole exome sequencing. Genome Biol. 2011; 12: R91
|
|
|
|
|
|
20）Harakalova M, van Harssel JJT, Terhal PA, et al. Dominant missense mutations in ABCC9 cause Cantú syndrome. Nat Genet. 2012; 44: 793-6
|
|
|
|
|
|
21）Blue GM, Kirk EP, Giannoulatou E, et al. Targeted next-generation sequencing identifies pathogenic variants in familial congenital heart disease. J Am Coll Cardiol. 2014; 64: 2498-506
|
|
|
|
|
|
22）Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature. 2013; 498: 220-3
|
|
|
|
|